Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells.
In this study, we have explored the possibility of the combination of the high reactivity of nano Fe3O4 or Au nanoparticles and daunomycin, one of the most important antitumor drugs in the treatment of acute leukemia clinically, to inhibit MDR of K562/A02 cells. Initially, to determine whether the magnetic nanoparticle Fe3O4 and Au can facilitate the anticancer drug to reverse the resistance of cancer cells, we have explored the cytotoxic effect of daunomycin (DNR) with and without the magnetic nano-Fe3O4 or nano-Au on K562 and K562/A02 cells by MTT assay. Besides, the intracellular DNR concentration and apoptosis of the K562/A02 cells was further investigated by flow cytometry and confocal fluorescence microscopic studies. The MDR1 gene expression of the K562/A02 cells was also studied by RT-PCR method. Our results indicate that 5.0 x 10(-7) M nano-Fe3O4 or 2.0 x 10(-8) M nano-Au is biocompatible and can apparently raise the intracellular DNR accumulation of the K562/A02 cells and increase the apoptosis of tumor cells. Moreover, our observations illustrate that although these two kinds of nanoparticles themselves could not lower the MDRI gene expression of the K562/A02 cells, yet they could degrade the MDR1 gene level when combining with anticancer drug DNR. This raises the possibility to combine the nano-Fe3O4 or nano-Au with DNR to reverse the drug resistance of K562/A02 cells, which could offer a new strategy for the promising efficient chemotherapy of the leukemia patients.
Chen
Bao-An
BA
Department of Hematology, The Affiliated Zhongda Hospital of Southeast University, Nanjing 210009, P.R. China. cba8888@hotmail.com
Dai
Yong-Yuan
YY
Wang
Xue-Mei
XM
Zhang
Ren-Yun
RY
Xu
Wen-Lin
WL
Shen
Hui-Ling
HL
Gao
Feng
F
Sun
Qian
Q
Deng
Xiao-Jing
XJ
Ding
Jia-Hua
JH
Gao
Chong
C
Sun
Yun-Yu
YY
Cheng
Jian
J
Wang
Jun
J
Zhao
Gang
G
Chen
Ning-Na
NN
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003630:Daunorubicin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005290:Ferric Compounds / Q000008:administration & dosage* / Q000737:chemistry; D006046:Gold / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D020014:K562 Cells; D007938:Leukemia / Q000473:pathology* / Q000503:physiopathology*; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry
D005290:Ferric Compounds; C000499:ferric oxide; D006046:Gold; D003630:Daunorubicin